Author/Editor
Hilary Kramer
Publisher
InvestorPlace Media
Description
Weekly newsletter that trades low-priced stocks (used to be “Breakout Stocks Under $5” and then “Breakout Stocks Under $10) with “breakout potential” either because they’re at bargain prices, are in turnaround, or are about to get a sudden growth surge.
Overall Rating
Rating: 3.8/5. From 4 votes.
Please wait...
2.5
Rating from 16 votes
If you’ve subscribed to Breakout Stocks, please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.
Investment Performance
Rating from 6 votes
Rating: 1.7/5. From 6 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 4 Votes
- 1 Stars 2 Votes
Quality Of Writing/Analysis
Rating from 3 votes
Rating: 2.7/5. From 3 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 0 Votes
- 3 Stars 2 Votes
- 2 Stars 1 Votes
- 1 Stars 0 Votes
Value For Price
Rating from 3 votes
Rating: 1.7/5. From 3 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 2 Votes
- 1 Stars 1 Votes
Customer Service
Rating from 4 votes
Rating: 3.8/5. From 4 votes.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 1 Votes
- 3 Stars 2 Votes
- 2 Stars 0 Votes
- 1 Stars 0 Votes
Very poor customer service, stock picks and the price is outrageous! She sends out emails but they are rarely informative and frequently just “teasers” for her other website.She does have recommendations on a regular basis but she has more losers than winners and continuously touts her one or two winners. I have seen Hillary on CNBC and believe her to be a very talented trader but am NOT impressed with her “Breakout Stocks Under $5.” They offer a “money-back” guarantee but they never reply to your emails.
Just found this teaser in Yahoo INO message board
Do you think she is talking about INO?
Hilary Kramer teaser e-mail: If You Buy Only ONE Small Cap Stock in 2014…
If You Buy Only ONE Small Cap Stock in 2014…
Breaking News:
Stage Set for Massive Run-Up:
Shares up 270.6% in last 12 months… yet still ‘deep value priced’ at only $3.55 per share
Phase 1 (complete) = Lead vaccine displays potentially revolutionary ‘shutdown effect’ on spread of cervical cancer. Of 18 patients tested in phase 1… all 18 showed an immune response!
Phase 2 (results out mid-2014) = Optimism rife for results of larger study. Positive news could have a major impact on the stock price.
Investors: Don’t Miss Out! You Must RSVP within 48 hours;
no exceptions, please.
Fellow Investor,
You’d better pounce on this secret before it goes viral…
One of my Top 5 Buys could be about to go sky-high.
Correction: It already has. But a new trigger — to be activated in the next 90 days — looks likely to send this one into the stratosphere.
You see, I’ve hinted for months that biotech stocks could rally higher in 2014.
But I had my eye on one company in particular. Share price and market cap have been inching up, and we’re now at a major ‘tipping point’…
A 270.6% climb in the last 12 months? Exactly.
Why all the buzz around this stock?
Like I hinted earlier, their lead product candidate is fresh off outstanding results during phase 1, or ‘proof-of-concept’ testing.
In that study, 18 women who had previously been treated for precancerous changes in the cervix were tested. Amazingly, all 18 patients showed an immune response to the vaccine.
Furthermore, a T-cell response (which can kill off HPV-infected cells) was triggered in 14 patients. That’s a remarkable 78% ‘cancer shutdown’ efficacy rate.
The news just gets better and better for cancer victims. And yes, for investors, too.
I’ve the best news of all for now…
“You don’t even need amazing news — or to wait 90 days — to make $10,000 or more on this play.”
Management is extremely bullish about Phase 2 results which will be announced during Q2 or Q3.
They’re doing road shows… investor presentations… the whole lot.
And believe me, they’re not the only ones riding high right now…
Could this tiny $3.55 company REALLY become the next Merck or GlaxoSmithKline?
Guess what. If approved, their ‘cancer killer’ will go head-to-head against the big boys. Yes, I’m talking Merck’s Gardasil and GlaxoSmithKline’s Cervarix.
Both companies are $100 billion giants in the ever-expancing pharmaceutical field.
So what could happen to our tiny company?
Well, it could experience an immediate injection of $540 million in annual peak sales. (That’s a titanic boost for a small cap that reported less than $12 million in revenue for the first three quarters of 2013.)
Clearly, it’s all about the future here. And that future is potentially MASSIVE…
What we’ve witnessed so far is small beans compared to what may lie just ahead for us.
Here’s proof: Gardasil alone generated $1.83 billion in revenue during fiscal 2013.
Yes, $1,830,000,000 in sales last year. Can you imagine if our small cap hits the jackpot – and gets a shot to battle it out with Merck? I’d love to see it…
Plus our cancer “miracle cure” comes with a few nice bonuses that the big guys on the block can’t match.
For example, both of their top vaccines are no longer recommended for girls ages 12 to 16 in Japan due to major safety concerns.
I’m happy to say there have been no health or safety concerns raised in studies so far.
Friend, I don’t often lose my calm reserve. But know what I think? We could be staring at the long-awaited ‘miracle cure’ for at least some forms of cancer.
WHAT’S COVERED?
The Company’s clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines.
Good news for everyone… but especially for savvy investors like us.
First, because our Pennsylvania-based drug company has the exclusive patent…
Second, because it’s your chance to get in on the GROUND FLOOR of what could be the decade’s biggest medical windfall. Perhaps the biggest of all time!
Heck, we don’t even need to wait 90 days to see how the Phase 2 trials go…
Current price momentum will see us through!
It’s the FIRST biotech stock
I’d recommend anybody buy this year
My name is Hilary Kramer, editor and founder of Breakout Stocks Under $10.
Those of you who know me might think I’ve ‘lost my marbles’.
Why? You know I do NOT chase ‘hot tips’… time the market… or try to call its highs and lows. I’ve been around long enough to know these are your best routes to getting burned — and doing permanent damage to your portfolio.
Instead, I launched Breakout Stocks to connect my readers with companies best suited to weather the inevitable storms… and prosper from the good times.
My sweet spot? Small caps flying under the radar… and hiding a secret ‘trigger that will let them dominate their niche (or will soon).
I’ve had staggering success since launching this breakthrough service.
So while it may appear I’m putting all my chips on a one-off cancer miracle cure…
I certainly am not!
My track record proves it.
I’m on a phenomenal hot streak. I’ve posted 13 winners in a row… going back to October 2013.
“What have you done for me lately?” Here it is in a nutshell:
See how just one company in the chart above is in the healthcare space?
That’s about to change. BIG-time.
Six Months from Now — You’ll have Missed it…
I’ll cut to the chase. Here’s why this small-cap pharma deserves top spot in your portfolio.
It ticks every one of my boxes…
Under $1 billion in market cap… top-flight management leading the way… a huge secret ‘up their sleeve’…… and happily flying under the radar (until lately)…
These are a few key triggers I use to identify world-beater breakout stocks like this.
But sorry, it’s almost impossible to keep this latest one under my hat any longer. Media coverage is on the verge of exploding…
Six months from now, you’ll have wished you got in NOW.
OK, their share price is already up 270.6% in 12 months. But please don’t let that slow you down.
The truly meteoric price growth is still ahead, if all proceeds as planned. And all signals are go right now.
I could go on and on about why you need to own a slice of this company. But I’ll tell you what…
I’d rather send you a Special Intelligence Briefing I just prepared called My Top 5 Small Cap ‘Surge Rockets’ for 2014.
Inside, in black and white, you’ll find my reasons why I’m so bullish on this exciting drug company… plus four more Strong Buys for 2014……………….. Less
Yes Yum she is definitly talking about INO.Good luck in your investments.Cheers,Glenn
Anyone has any experience with Michael Lombardi’s Crash Survival Letter? It sounds interesting but is it worth the $195/year? Thanks in advance!
Poor …..she never mentions loosers and checking gives overall poor results…and she NEVER anwers e-mails….even ones asking her to stop sending out bumph.
JOHN m.
Joined this hoping for half the results she promises. However, of the 54 picks made from Feb 2016 through Sept 2017, the total gain was 1.85% using a 100 share basis for each trade. Not a very good return. I asked for my pro-rated refund which the promptly provided.